These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 15571968)

  • 1. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
    Formento P; Hannoun-Levi JM; Fischel JL; Magné N; Etienne-Grimaldi MC; Milano G
    Eur J Cancer; 2004 Dec; 40(18):2837-44. PubMed ID: 15571968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
    Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
    Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
    Formento P; Hannoun-Levi JM; Gérard F; Mazeau C; Fischel JL; Etienne-Grimaldi MC; Gugenheim J; Milano G
    Eur J Cancer; 2005 Jul; 41(10):1467-73. PubMed ID: 15919200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.
    Zhang KX; Moussavi M; Kim C; Chow E; Chen IS; Fazli L; Jia W; Rennie PS
    Cancer Gene Ther; 2009 Nov; 16(11):820-31. PubMed ID: 19373278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for combining hormonal and nonhormonal growth factor inhibition.
    Wakeling AE; Nicholson RI; Gee JM
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4350s-4355s; discussion 4411s-4412s. PubMed ID: 11916224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of EGFR and HER-2 in colon cancer cell lines.
    Giannopoulou E; Antonacopoulou A; Floratou K; Papavassiliou AG; Kalofonos HP
    Cancer Chemother Pharmacol; 2009 May; 63(6):973-81. PubMed ID: 18751705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
    Kondo N; Ishiguro Y; Kimura M; Sano D; Fujita K; Sakakibara A; Taguchi T; Toth G; Matsuda H; Tsukuda M
    Oncol Rep; 2008 Aug; 20(2):373-8. PubMed ID: 18636200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
    Ziada A; Barqawi A; Glode LM; Varella-Garcia M; Crighton F; Majeski S; Rosenblum M; Kane M; Chen L; Crawford ED
    Prostate; 2004 Sep; 60(4):332-7. PubMed ID: 15264245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines.
    Kim EM; Lobocki C; Dubay L; Mittal VK
    Am J Surg; 2009 Mar; 197(3):331-6. PubMed ID: 19245910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate.
    Li Y; Cozzi PJ; Qu CF; Zhang DY; Abbas Rizvi SM; Raja C; Allen BJ
    Cancer Lett; 2004 Mar; 205(2):161-71. PubMed ID: 15036648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
    Legrier ME; Oudard S; Judde JG; Guyader C; de Pinieux G; Boyé K; de Cremoux P; Dutrillaux B; Poupon MF
    Br J Cancer; 2007 Jan; 96(2):269-76. PubMed ID: 17211467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro modeling of HER2-targeting therapy in disseminated prostate cancer.
    Andersson J; Rosestedt M; Asplund V; Yavari N; Orlova A
    Int J Oncol; 2014 Nov; 45(5):2153-8. PubMed ID: 25176024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
    Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factors and their receptors: new targets for prostate cancer therapy.
    Barton J; Blackledge G; Wakeling A
    Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.